Lantern Pharma Inc. Stockholders Equity

Quick Answer

Lantern Pharma Inc. reported Stockholders Equity of $6.53 million for fiscal year 2025.

Lantern Pharma Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $6.53M -69.2%
2024 $21.19M -48.2%
2023 $40.91M -27.0%
2022 $56.04M -21.7%
2021 $71.57M +263.3%
2020 $19.70M +1988.3%
2019 $943.3K +567.4%
2018 -$201.8K

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $9.59M -64.0% -23.4%
June 30, 2025 $12.52M -59.5% -25.4%
March 31, 2025 $16.78M -53.1% -20.8%
December 31, 2024 $21.19M -48.2% -20.3%
September 30, 2024 $26.60M -41.4% -14.0%
June 30, 2024 $30.93M -35.9% -13.5%
March 31, 2024 $35.77M -32.0% -12.6%
December 31, 2023 $40.91M -27.0% -9.9%
  • Lantern Pharma Inc. showed a decrease of -69.2% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2018–2025 period, Lantern Pharma Inc.’s stockholders equity has grown by 3338.0% (from -$201.8 thousand to $6.53 million).
  • The most recent figure is from Lantern Pharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment